HOME
HIV and AIDS
Hepatitis B
Hepatitis C
HIV-HCV Coinfection
HIV-HBV Coinfection
HIV and AIDS Articles on:
  FDA-approved Treatments
 
Experimental Treatments
 
Top New Articles
HOME PAGE

Opportunistic Infections
Tuberculosis / Candidiasis / Pneumonia
CMV Retinitis

Updated Guidelines for Prevention and Treatment of Opportunistic Infections in HIV Positive Adults, Adolescents, and Children

Excess Risk of Opportunistic Diseases and Death Remains after Reinitiating HAART following Treatment Interruption - 10/24/08

Lack of HAART and Low CD4 Cell Count are Linked to Non-AIDS-related as well as Opportunistic Conditions - 10/03/08

HIV Positive Tuberculosis Patients Need to Start Antiretroviral Treatment Early - 9/25/08

Despite HAART, People with HIV Are Still At Risk for Life-threatening Progressive Multifocal Leukoencephalopathy (PML) - 9/12/2008

Cidofovir (Vistide) in Addition to Antiretroviral Therapy Is Not Effective for AIDS-related Progressive Multifocal Leukoencephalopathy (PML) - 9/12/2008

High HIV Viral Load Is a Risk Factor for Tuberculosis within 3 Months of Starting HAART - 8/26/08

Tuberculosis, HAART, and Survival in the THRio Cohort in Rio de Janerio, Brazil - 8/26/08

ournal Examines Treatment of Extensively Drug-resistant Tuberculosis as First Survey of Cases Is Reported in California - 8/26/08

Nevirapine (Viramune) May Be Less Effective When Combined with Tuberculosis Treatment - 8/05/08

Tuberculosis Presents Major Challenges to HIV Treatment in Developing Countries - 7/25/08

Studies Show High Rates of Cancer-causing Human Papillomavirus Infection among HIV Positive Women in Africa - 7/15/08

Key Tuberculosis (TB) Drug Isoniazid Fails to Protect Infants of HIV Positive Mothers from TB Acquisition or Death - 7/18/08

New Test Can Rapidly Diagnose Multidrug-resistant Tuberculosis - 7/08/08

HAART Regimen Changes Due to Drug Toxicities in HIV Positive People with Virological Suppression - 6/13/08


HIV Patients Taking Efavirenz (Sustiva) Experience Fewer Oral Lesions than Those on Protease Inhibitors - 6/13/08

Anti-PGL-TB-1 Antibodies Predict Lack of Immune Restoration Syndrome in HIV Positive Patients with Tuberculosis - 6/06/08

Bacterial Vaginosis, Not HIV, Is Primarily Responsible for Increased Concentrations of Vaginal Proinflammatory Cytokines - 6/03/08

Oral Therapy Reduces Incidence of Bacterial Vaginosis and Promotes Vaginal Health in HIV Positive Women - 6/03/08

Long-term Alcohol Abuse Is Linked to Worse Liver Fibrosis in HIV Positive Veterans with or without HCV Coinfection - 6/03/08

Gastrointestinal Symptoms
Are Uncommon during Early HIV Infection, Despite CD4 Cell Depletion in the Gut - 5/23/08

Inflammatory Bowel Disease in HIV Positive Individuals - 5/23/08

Higher CD4 Count Predicts Lower Risk of AIDS-related and Non-AIDS Illness, even above 350 Cells/mm3 - 5/06/08

NIAID Research Priorities to Fight Drug-resistant Tuberculosis - 5/06/08

Treatment Options for Osteopenia and Osteoporosis in HIV Patients - 5/02/08

Prevalence and Outcomes of Liver Cirrhosis in HIV Positive People  - 4/11/08

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors (PIs)
Note: Most PIs are now used in combination with low-dose ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase  Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)